OPTIMIZATION OF PALLIATIVE CHEMOTHERAPY AND IMPROVEMENT OF QUALITY OF LIFE IN PATIENTS WITH BREAST CANCER ACCOMPANIED BY PULMONARY METASTASES: A STRUCTURED LITERATURE REVIEW

Authors

  • Khalmatov Bakhram Akbarovich

    Head of the Palliative Care Department Tashkent Regional Branch of the Republican Specialized Scientific and Practical Medical Center of Oncology and Radiology (RSSPMCOR), Uzbekistan

    Author

Keywords:
Breast cancer, pulmonary metastases, palliative chemotherapy, quality of life, metastatic breast cancer, supportive care, oncology
Abstract

Background: Pulmonary metastases are frequently observed in advanced breast cancer and significantly contribute to morbidity and mortality. Palliative chemotherapy remains an essential component of treatment, aiming to control disease progression, alleviate symptoms, and maintain quality of life.
Objective: To analyze contemporary evidence regarding optimization of palliative chemotherapy and quality-of-life improvement in patients with breast cancer accompanied by pulmonary metastases.
Materials and Methods: A structured literature review was conducted using publications indexed in PubMed, Scopus, Web of Science, and Google Scholar. Studies published between 2015 and 2025 addressing palliative chemotherapy, metastatic breast cancer, pulmonary metastases, supportive care, and quality-of-life outcomes were included.

References

1. Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2024: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians. 2024;74(3):229–263.

2. Cardoso F., Paluch-Shimon S., Senkus E., Curigliano G., Aapro M.S., André F., et al. 5th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 5). Annals of Oncology. 2020;31(12):1623–1649.

3. Gennari A., André F., Barrios C.H., Cortés J., de Azambuja E., DeMichele A., et al. ESMO Clinical Practice Guideline for the Diagnosis, Staging and Treatment of Patients with Metastatic Breast Cancer. Annals of Oncology. 2021;32(12):1475–1495.

4. Gradishar W.J., Moran M.S., Abraham J., Aft R., Agnese D., Allison K.H., et al. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Journal of the National Comprehensive Cancer Network. 2024;22(5):331–412.

5. Harbeck N., Penault-Llorca F., Cortes J., Gnant M., Houssami N., Poortmans P., et al. Breast Cancer. Nature Reviews Disease Primers. 2019;5(1):66.

6. Loibl S., Poortmans P., Morrow M., Denkert C., Curigliano G. Breast Cancer. Lancet. 2021;397(10286):1750–1769.

7. Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.A., Yusof M.M., et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2020;382(9):810–821.

8. Modi S., Jacot W., Yamashita T., Sohn J., Vidal M., Tokunaga E., et al. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer. New England Journal of Medicine. 2022;387(1):9–20.

9. Bardia A., Hurvitz S.A., Tolaney S.M., Loirat D., Punie K., Oliveira M., et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine. 2021;384(16):1529–1541.

10. Rugo H.S., Bardia A., Marmé F., Cortés J., Schmid P., Loirat D., et al. Overall Survival with Sacituzumab Govitecan in Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer. Journal of Clinical Oncology. 2023;41(10):1743–1754.

11. Montazeri A. Health-Related Quality of Life in Breast Cancer Patients: A Bibliographic Review of the Literature from 2018 to 2024. Journal of Experimental & Clinical Cancer Research. 2024;43(1):112.

12. Di Maio M., Basch E., Bryce J., Perrone F. Patient-Reported Outcomes in the Evaluation of Toxicity of Anticancer Treatments. Nature Reviews Clinical Oncology. 2016;13(5):319–325.

13. Ferrell B.R., Temel J.S., Temin S., Alesi E.R., Balboni T.A., Basch E.M., et al. Integration of Palliative Care into Standard Oncology Care: ASCO Guideline Update. Journal of Clinical Oncology. 2017;35(1):96–112.

14. Hui D., Bruera E. Models of Integration of Oncology and Palliative Care. Annals of Palliative Medicine. 2021;10(3):290–298.

15. Temel J.S., Greer J.A., El-Jawahri A., Pirl W.F., Park E.R., Jackson V.A., et al. Effects of Early Integrated Palliative Care in Patients with Advanced Cancer. Journal of Clinical Oncology. 2017;35(8):834–841.

16. Earle C.C., Landrum M.B., Souza J.M., Neville B.A., Weeks J.C., Ayanian J.Z. Aggressiveness of Cancer Care Near the End of Life and Its Impact on Quality of Life. Journal of Clinical Oncology. 2020;38(15):1723–1731.

17. Schmid P., Cortes J., Dent R., Pusztai L., McArthur H., Kümmel S., et al. Event-Free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer. New England Journal of Medicine. 2022;386(6):556–567.

18. Burstein H.J., Somerfield M.R., Barton D.L., Dorris A., Fallowfield L.J., Jain D., et al. Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology. 2021;39(35):3959–3977.

19. Cardoso F., Kyriakides S., Ohno S., Penault-Llorca F., Poortmans P., Rubio I.T., Zackrisson S., Senkus E. Early Breast Cancer: ESMO Clinical Practice Guidelines. Annals of Oncology. 2019;30(8):1194–1220.

20. World Health Organization. WHO Guide for Effective Palliative Cancer Care. Geneva: World Health Organization; 2023.

Downloads
Published
2026-06-06
Issue
Vol. 2 No. 6 (2026)
Section
Articles
License
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

How to Cite

OPTIMIZATION OF PALLIATIVE CHEMOTHERAPY AND IMPROVEMENT OF QUALITY OF LIFE IN PATIENTS WITH BREAST CANCER ACCOMPANIED BY PULMONARY METASTASES: A STRUCTURED LITERATURE REVIEW. (2026). Eureka Journal of Health Sciences & Medical Innovation, 2(6), 122-132. https://eurekaoa.com/index.php/5/article/view/1236